GeDDiS Trial: Gemcitabine and docetaxel versus doxorubicin as first-line treatment sarcomas Last updated on Apr 21, 2024 Previous Trabectedin Next GOG 277: Adjuvant Gemcitabine Plus Docetaxel Followed by Doxorubicin Versus Observation for High-Grade Uterine Leiomyosarcoma
